PolyPeptide Group AG (0AAJ.L) LSE
38.05
+0.1963(+0.52%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
PolyPeptide Group AG
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1362
First IPO Date
November 12, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Juan Jose Gonzalez | Chief Executive Officer | 1.7M | 1972 |
| Christophe Chevalier | Head of Technical Department - Braine | 0 | N/A |
| Tim Brandl | Interim CFO and Director of Investor Relations, Financial Planning & Analysis | 0 | N/A |
| Andreas Liese | Corporate Compliance Manager | 0 | N/A |
| Monika Casanova | Chief Human Resources Officer | 0 | 1979 |
| Christina Del Vecchio | Chief Legal Officer & Corporate Secretary | 0 | 1978 |
| Rene Vestergaard | Director of Corporate Finance | 0 | N/A |
| Trishul Shah | Interim Director Global Sales & Marketing | 0 | N/A |
| Michael Staheli | Head of Investor Relations & Corporate Communications | 0 | 1965 |
| Olivier Ludemann-Hombourger | Director of Global Innovation & Technology | 0 | 1972 |
Description
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
